Sunday, November 1, 2015

Tracing back the story of asylums in colonial India



CHENNAI: In Great Britain, mental illness was a serious subject of research during the 19th century, with leading scholars coming up with fascinating aspects of asylums in the region. But how about the madness in colonial India? The story of the Cuttack Lunatic Asylum (1860-1900) highlights a host of complexities. "The idea behind establishing the Cuttack asylum was not to treat patients but to confine the 'lunatics' and make life secure for those outside," according to Biswamoy Pati, author and senior fellow at the Nehru Memorial Museum and Library, New Delhi. 

"Many problems faced by those who were considered to be 'mad' were ironically conditioned by the presence and expansion of the colonies and its internal collaborators over the 19th century," said Pati, who was speaking on "Confining 'lunatics': the Cuttack Asylum" at a seminar conducted by the department of Humanities and Social Sciences at IIT-Madras on Saturday. 

Focusing on a micro-study about the Cuttack lunatic asylum, Pati explored certain dimensions that are intrinsically linked with the context and are rooted in the economic and social history of the region. "Some incidents that took place inside the asylum show how by criminalizing 'insanity', colonialism had succeeded in brutalizing an inmate who had never acted violently," he said. 

The Cuttack Lunatic Asylum closed down in the context of the partition of Bengal. "In March 1906, 37 inmates (36 males and one female) of this asylum were shifted to the Berhampore Asylum. The most striking aspect of this asylum's existence demonstrates how colonization itself was entrapped by the idea of 'unchanging east' that it had invented. The virtually unchanging existence of the Cuttack asylum served to reinforce this myth," he said. 

The logic of criminality associated with the insane and the manner in which the poor were located in the health programmes were atrocious. "Nothing seems to have been learnt from the past experiences. Today, the Indian ruling classes are busy dismantling the public health system that had developed in post-colonial India, even as they re-enact the moribund policies of the colonial ruling classes," said Pati.

Wednesday, October 28, 2015

Dead could be kept alive, interacted in future: UK academic

You are here: News HomeScience

Dead could be kept alive, interacted in future: UK academic

LONDON: Deceased family members in future could be brought back to life, interacted with and kept alive forever in a virtual reality accurately created from their movements and social media history, a UK-based academic has claimed.

Computers will be advanced enough in around 50 years that they can create "synthetic digital life" based upon people's past movements, preferences and history on social media, Simon McKeown, a reader in Animation and Post Production at Teesside University in Middlesborough, has said.

These avatars would be created using a process called "photogrammetry", which can accurately reconstruct a virtual 3D shape of a human being from existing photographs and video.

Computer voice synthesis will take into account local and regional accents to deliver a more accurate representation of what they sounded like.

Dubbing the idea as 'Preserved Memories', McKeown claims that people would be able to construct a reality to avoid ever having to say goodbye to loved ones.

"In the future with Preserved Memories, you will never have to experience the loss of a loved one. You will be able to add to your family tree and select new family members, including famous faces and legends, all of whom will already know about you," McKeown was quoted as saying by 'The Telegraph'.

"Using emotion-sensitive human-computer interaction our artificially intelligent participants continue to acquire ongoing knowledge long after their death - they evolve digitally and do not die," he said.

Showcasing 'Preserved Memories' at an exhibition in Prague, McKeown said this life form will be up to date and informed of "your daily activities through GPS, Wifi, health and fitness tracking, consumer records and much more."

"They will know if you have passed your exam, driving test, flown on holiday, bought new shoes, ditched your boyfriend. They will know what you tell it on social media and also by the constant tracking that occurs every day," he said.

McKeown said our prime data feeds meant digital participants instantly know what we have done and can sense our physical mood and excitement.

Common heartburn drugs may damage your kidney


Common heartburn drugs may damage your kidney
Representative image.
NEW YORK: Increased use of certain medications commonly used to treat heartburn and acid reflux may have damaging effects on the kidneys, say researchers, including one of Indian-origin.

The researchers looked at the effects of the drugs called proton pump inhibitors (PPIs) on chronic kidney disease (CKD).

In one study, Pradeep Arora from State University of New York and his team found that among 24,149 patients who developed CKD between 2001 and 2008 (out of a total of 71,516 patients), 25.7 per cent were treated with PPIs.

PPI use was linked with a 10 per cent increased risk of CKD and a 76 per cent increased risk of dying prematurely.

"As a large number of patients are being treated with PPIs, health care providers need to be better educated about the potential side effects of these drugs, such as CKD," Arora pointed out.

In another study, Benjamin Lazarus from Johns Hopkins University and his colleagues followed 10,482 adults with normal kidney function from 1996 to 2011.

They found that PPI users were between 20 per cent and 50 per cent more likely to develop CKD than non-PPI users, even after accounting for baseline differences between users and non-users.

This discovery was replicated in a second study, in which over 240,000 patients were followed from 1997 to 2014.

"In both studies, people who used a different class of medications to suppress stomach acid, known as H2-blockers, did not have a higher risk of developing kidney disease," Lazarus pointed out.

"If we know the potential adverse effects of PPI medications we can design better interventions to reduce overuse," Lazarus noted.

The findings will be presented at ASN (American Society of Nephrology) Kidney Week 2015 to be held at San Diego Convention Centre from November 3-8.

Sunday, October 25, 2015

the man was actually his son's uncle.--the father of the boy is effectively the man's own unborn twin.


'Human chimera': Man fails paternity test because genes in his saliva are different to those in sperm


'Human chimera': Man fails paternity test because genes in his saliva are different to those in sperm
File Photo: A DNA model (AFP)
A man from Washington has reportedly been informed that the father of his son is effectively his unborn brother.

The 34-year-old man is the first ever reported case of a paternity test being fooled by a human chimera, someone with extra genes absorbed from a twin lost in early pregnancy.

Approximately one in eight single childbirths are thought to start as multiple pregnancies and occasionally cells from the miscarried siblings are sometimes absorbed in the womb by a surviving twin.

According to Buzzfeed, the Washington couple took a paternity test after their son's blood type didn't match that of either parent. After having a child with the help of fertility clinic procedures, they feared that sperm donors may have potentially been mixed up.

After the initial failed fertility test, they took a genetic ancestry test which suggested that the man was actually his son's uncle.

The father's sperm was found to have 10 per cent of a genetic match to the infant. The genes in his sperm were different to that in his saliva and it has been concluded that the father of the boy is effectively the man's own unborn twin.

There have been chimera cases in the past. Karen Keegan from Boston found that her blood cells had one set of genes and her ovaries held distinctly different ones. Those ovaries had produced the eggs that led to two of Keegan's sons holding genes different from her own.

The true genetic mother was a twin sister that she never knew and who was never born.

Searches for chimeras are incredibly complicated as the genes only feature in detectable amounts in very few organs. As more people turn to fertility clinics to help them have children, chimerism may become more common, as fertility treatments are more likely to lead to multiple births.

Organs on Demand- 3D Printers Could Build Hearts, Arteries-With consumer-level 3D printers that cost less than $1,000


Organs on Demand- 3D Printers Could Build Hearts, Arteries

Bioprinted Coronary Artery
A 3D printer creating a coronary artery structure.
Credit: Carnegie Mellon University College of Engineering
Off-the-shelf 3D printers could one day help create living organs to aid in repairing the human body, researchers say.
Scientists have developed a way to 3D print models of various anatomical structures, including hearts, brains, arteries and bones. In the future, this process could be used to create 3D-printed soft implants in which living tissue can grow to form organs. Another application for this innovative technology could be food printers, reminiscent of the replicators seen on the TV show "Star Trek," the scientists added.
A 3D printer is a machine that creates items from a wide variety of materials: plastic, ceramic, glass, metal and even more unusual ingredients, such as living cells. The device works by depositing layers of material, just as ordinary printers lay down ink, except 3D printers can also lay down flat layers on top of each other to build 3D objects. [7 Cool Uses of 3D Printing in Medicine]

Conventional 3D printers manufacture objects from rigid materials, with each layer receiving a sturdy foundation from the layers below. However, printing soft materials has proven to be difficult, akin to building an object out of Jell-O.
"Metals, ceramics and stiff polymers have been 3D printed for many, many years, but soft materials, those that can deform under their own weight, have been more challenging to support during the print process," said Adam Feinberg, a biomedical engineer at Carnegie Mellon University and senior author of the new study.
Researchers have used 3D printers to create rigid medical devices customized for individual patients; those devices include hearing aids, dental implants and prosthetic hands. However, using 3D printers to create soft implants, a process known as bioprinting, could provide alternatives to traditional transplants for repairing or replacing damaged organs, Feinberg said.
"The potential applications we envision are in the area of tissue engineering — essentially, 3D printing scaffolds and cells to regrow tissues and organs," Feinberg told Live Science.
The scientists have developed a way of 3D printing soft materials inside a bath of supportive fluid that contains gelatin powder, similar to the type that can be found in a supermarket.
"We print one gel inside of another gel, which allows us to accurately position the soft material as it's being printed, layer by layer," Feinberg said in a statement.
Using medical imaging data, the researchers used their new technique, called FRESH, or "Freeform Reversible Embedding of Suspended Hydrogels," to print simplified, proof-of-concept anatomical structures. These were made of a variety of biological materials, such as the collagen found in tendons and ligaments. The test structures included a human femur, a human coronary artery, a five-day embryonic chick heart and the external folds of a human brain. [5 Crazy Technologies That Are Revolutionizing Biotech]
The models were printed with a resolution of about 200 microns, the researchers said. (In comparison, the average human hair is about 100 microns wide.)
"We can take materials like collagen, fibrin and alginate, which are the types of materials the body uses to build itself, and 3D print them," Feinberg said. "We can now build tissue-engineering scaffolds using these materials in incredibly complex structures that more closely match those of real tissues and organs in the body." (Fibrin helps make up blood clots, while alginate is found in many seaweeds.)
In this new technique, the support gel around the 3D structures can be easily melted away and removed by heating it to body temperature. Such temperatures would not damage any delicate biological molecules or living cells printed out in the method, the scientists said.
The researchers cautioned that they have not yet bioprinted organs. "This work is an important step in that direction by enabling us to use biological materials that we believe are necessary to do this," Feinberg said. "However, years of research are still required."
In the future, the researchers plan to incorporate real heart cells into their work, they said. The 3D-printed structures will serve as scaffolds in which the cells can grow and form heart muscle.
Bioprinting living cells is a growing field, but, until now, most 3D bioprinters retailed for more than $100,000, or required specialized expertise to operate (or both), limiting the possibilities for the technique's widespread adoption. However, this new method can be done with consumer-level 3D printers that cost less than $1,000. It also uses open-source software that the researchers say they invite others to hack and improve.
"Our vision is that other research groups can take this technology and apply it broadly to other tissue-engineering and soft-materials 3D-printing challenges," Feinberg said.
The scientists detailed their findings online today (Oct. 23) in the journal Science Advances.

poster child for big pharmaceutical GREED.--Drug Goes From $13.50 a Tablet to $750, Overnight

Daraprim
NEW YORK — The company that hiked the price of Daraprim, a drug used to treat AIDS patients, is backing off. Pharmaceutical company Turing increased the price of a drug called Daraprim from $13.50 to $750 a pill and its CEO, Martin Shkreli, quickly became the focus of public anger.Sep 23, 2015
 Image result for greedy man

Price being lowered on medicine that jumped from $13 to ...

wreg.com/.../price-being-lowered-on-medicine-that-jumped-from-13-to-75...

Drug Goes From $13.50 a Tablet to $750, Overnight - The ...

www.nytimes.com/.../a-huge-overnight-increase-in-a-drugs-price-raises-pro...
Sep 20, 2015 - The price of the drug, called Daraprim, a standard of care for treating a life-threatening parasitic infection, went to $750 a tablet from $13.50.
Image result for greedy man


In a demonstration of arbitrary pricing of medicines, pyremethamine, used to treat protozoal infections, went from $13 to $750 a pill in the US,
In a demonstration of arbitrary pricing of medicines, pyremethamine, used to treat protozoal infections, went from $13 to $750 a pill in the US, an over 5,000% increase, and down to $1 per pill for a new version, all in a span of just over a month. The new $1 pill is being produced by a small San Diego-based company called Imprimis Pharmaceuticals.

Daraprim, or branded pyremethamine, was bought from its producer by Turing Pharmaceuticals owned by a hedge fund manager Martin Shkreli, who then hiked the price to $750 becoming "the poster child for big pharmaceutical greed".

Despite widespread protest over the massive price hike of a 62-year-old off-patent drug, Shkreli failed to bring down the price after promising he would do so. Daraprim, which treats an uncommon parasitic infection, toxoplasmosis, is critical for treating immunocompromised patients of HIV/AIDS, cancer and pregnant women.
Image result for greedy man
Imprimis Pharmaceuticals is a compounding pharmacy, which in the US means a company which mixes approved drug ingredients to prepare medicines based on a doctor's prescription. This three-and-a-half year old company is producing a formulation of Daraprim's active ingredients, pyremethamine and leucovorin.

The Imprimis formulation is not approved by the US Food and Drug Administration (FDA), but compounded formulations are allowed to be sold legally in the US as long as it is through a doctor's prescription. Compounding pharmacies do not need FDA approval unlike large pharma companies that mass produce drugs on complex production lines. The increasingly complicated regulations around FDA drug approval would have meant several years and millions of dollars for Imprimis and that would not have allowed it to keep the price affordable